Fig. 5
![Fig. 5](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12954-023-00743-8/MediaObjects/12954_2023_743_Fig5_HTML.png)
The most important considerations1 regarding HCV treatment locations among participants identified with current/former injection drug users and other participants (n = 170). Possibility to select up to three considerations. *p value < 0.05. 1Considerations choices which did not allow a comparison between groups were excluded